In the long human struggle to blunt the force of pandemic disease, two pharmaceutical companies stepped forward in late March 2021 with a tool shaped not for the masses but for the most vulnerable — those for whom infection carried the heaviest odds. GlaxoSmithKline and Vir Biotechnology asked the FDA to authorize emergency use of VIR-7831, a monoclonal antibody that, in clinical trials, reduced hospitalization and death among high-risk COVID-19 patients by 85 percent. The drug's design — targeting a stable region of the virus unlikely to mutate away from treatment — suggested it might endure
Markets Insider
· Mar 26, 2021
· health
· 1 min de leitura
High
Apuração: Verificado
GSK, Vir Seek FDA Emergency Authorization for COVID-19 Antibody VIR-7831
The treatment targets high-risk COVID-19 patients to prevent hospitalization and death, potentially reducing severe disease burden.
◉
Health & Medicine
8098 artigos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% correspondência
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% correspondência
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% correspondência
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Pharmaceutical development announcement with no direct geopolitical implications; routine FDA authorization request for COVID-19 treatment by GSK and Vir Biotechnology.
Escalation Risk
low
Confidence
HIGH
No significant power dynamics shifts. Standard regulatory process involving US FDA and potential EMA approval represents normal pharmaceutical governance channels.
Lente Econômica
📈
GSK and Vir Biotechnology seek FDA emergency authorization for VIR-7831, a monoclonal antibody demonstrating 85% efficacy in reducing COVID-19 hospitalization/death risk, signaling potential market expansion in therapeutic treatments.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare Services
Medical Devices & Diagnostics
Hospital & Healthcare Facilities
High-risk COVID-19 patients gain access to a highly effective early treatment option, potentially reducing hospitalizations, healthcare costs, and mortality. Consumers may experience reduced out-of-pocket expenses if covered by insurance or government programs.
FDA likely to expedite EUA review given strong efficacy data. Potential government procurement agreements for high-risk populations. Regulatory precedent for monoclonal antibody approvals may accelerate similar therapies. Pricing negotiations with CMS and private insurers anticipated.